Shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) were down 4.4% during trading on Monday . The company traded as low as $0.2294 and last traded at $0.2294. Approximately 3,320 shares changed hands during mid-day trading, a decline of 56% from the average daily volume of 7,466 shares. The stock had previously closed at $0.24.
Avenue Therapeutics Price Performance
The stock’s 50-day moving average price is $0.33 and its 200 day moving average price is $0.60. The firm has a market capitalization of $755,873.00, a PE ratio of 0.01 and a beta of -0.50.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.
The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.
Featured Stories
- Five stocks we like better than Avenue Therapeutics
- Elon Musk: This Could Turn $100 into $100,000
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
- Only 500 people today…
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
